Cytosurge announces spin-off of its micro-scale metal AM business unit

Cytosurge announces spin-off of its micro-scale metal AM business unit
Cytosurge’s AM business is now an independent entity and will operate under the name Exaddon AG

Cytosurge AG, Glattbrugg,
Switzerland, has announced a spin-off of its Additive Manufacturing business
unit, stating that the new company will focus on providing solutions for
processes and instruments in the field of microscopically small metal
components. The new independent entity will operate under the name
Exaddon AG, and will be led by Edgar Hepp who takes the role of CEO. 

According to Cytosurge, the
establishment of the spin-off company was initiated by exploring the
applicability of its proprietary FluidFM® technology to the field of
additive micro-manufacturing. Originally
developed at ETH Zurich a decade ago, FluidFM has already resulted in several
highly innovative solutions for customers in the pharmaceutical industry, as
well as academic research in the field of cell- and bioscience. 

Dr Pascal Behr, CEO of
Cytosurge, stated, “Given the unique nature of the Additive Manufacturing
business and specific requirements of our key target markets such as the
semiconductor industry, we are convinced that an independent company can
realise the high growth opportunities in this emerging market much better if it
can focus entirely on this key goal. We are very proud to announce today the
establishment of Exaddon AG for this purpose and I am convinced that Edgar and
his team will thrive.”

“We have developed a
ground-breaking manufacturing technology and have brought it to market
maturity. It enables our clients to additively manufacture high-end products at
an unprecedented level,” commented Hepp. “Exaddon AG is now
responsible for all Cytosurge AG projects related to Additive Manufacturing and
will continue to manage and develop them.”

Cytosurge states that the
companies will continue to collaborate closely and cooperate on selected
strategic projects.

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *